Company research / NSRX

Nasus Pharma Ltd (NSRX)

Build a valuation ↗↓ Download CSV

CIK 0002029039 · NYSE · Pharmaceutical Preparations

Sector Manufacturing
Incorporated L3
Fiscal year ends Dec 31

For the year ended 2025-12-31, Nasus Pharma Ltd reported revenue of $1.24B.

Key ratios (year ended 2025-12-31)

-0.4%

Operating margin

-0.5%

Net margin

-211.6%

Return on year-end equity

Beyond the statements

Follow the company.

Explore new filings, reported insider transactions and company relationships.

Open company research ↗

Latest selected filing: 6-K · 2026-09-04

Price chart

Chart and quotes by TradingView. Exchange coverage and delays vary.

Open chart on TradingView

Annual financials

Annual flows and balances are grouped by their actual period end. Select a figure to open its SEC filing. A dash means a matching observation is unavailable.

Period ended	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Revenue	$1.24B	—	—	—
Operating Income	-$4.90M	-$1.08M	-$1.15M	—
Net Income	-$5.86M	-$1.53M	-$1.05M	—
EPS (Diluted)	$-0.72	$-0.22	$-0.20	—
Total Assets	$5.00M	$717.0K	—	—
Total Liabilities	$2.24M	$3.93M	—	—
Shareholders' Equity	$2.77M	-$3.21M	-$3.80M	-$2.79M
Cash & Equivalents	$1.24M	$284.0K	$193.0K	—
Operating Cash Flow	-$4.92M	-$665.0K	-$1.03M	—
Capital Expenditures	$14.0K	—	—	—
Shares Outstanding	9.02M	7.36M	—	—
Weighted Average Diluted Shares	8.01M	7.03M	7.06M	—
EPS (Basic)	$-0.72	$-0.22	$-0.15	—